Scientific Advisory Board
Robert D. Brook, M.D.
Associate Professor of Medicine, University of Michigan
Dr. Brook is a well known specialist in the field of hypertension and preventive medicine. He has published several papers in prestigious medical journals and has taught several courses in preventive medicine to medical personnel and the lay public. Dr. Brook serves on the advisory boards of several pharmaceutical companies including Merck, Novartis, Pfizer, Takeda and Dai-Ichi Sankyo.
W. Virgil Brown, M.D.
Charles Howard Candler Professor of Medicine, Emory University
Dr. Brown is the Past President of the American Heart Association (1991-1992) and Past President of the National Lipid Association (2003-2005). He is also the editor of The Journal of Clinical Lipidology. Dr. Brown is well known for his research that began at the National Institutes of Health (NIH) where he served as chairman of the Metabolism Study Section. He is the founder of the prestigious Southeast Lipid Research Forum (instituted in 1992) and has chaired several Gordon Conferences on Lipid Metabolism. Dr. Brown was the recipient of the Golden Heart Award, the highest honor given by the American Heart Association for service to its mission over a lifetime.
Bobby V. Khan, M.D., Ph.D.
Director of Cardiovascular Research, Emory/Grady Memorial Hospital
Dr . Khan is the Director of Cardiovascular Research and Supervisor of the Vascular Research Laboratory at Emory/Grady Memorial Hospital in Atlanta, GA. He is also an Associate Professor of Medicine at Emory University School of Medicine and one of the founder of InVasc Therapeutics. In 2009, Dr. Khan was awarded a Fulbright Fellowship. He has published over 50 peer-reviewed papers, served as the principal investigator for several phase ll clinical trials and as a reviewer for several prestigious medical journals. Dr. Khan has also served on several planning committees for the scientific sessions of the American Collage of Cardiology and the American Heart Association,as well as on the scientific advisory boards of Sanofi-Aventis,Dai-lchi Sankyo and Bristol Myers Squibb.He has received grant support from the National Institutes of Health, Pfizer, Novartis, Amgen Boehringer Ingelheim and Forest Pharmaceuticals.
Sampath Parthasarathy, Ph.D., MBA
Klassen Chair and Professor of Surgery, Ohio State University
Dr. Parthasarathy currently holds an endowed chair in cardiothoracic surgery at The Ohio State University and is one of InVasc Therapeutics' founders. Dr. Parthasarathy is internationally-recognized for his work in the area of atherosclerosis and has been continually funded by the National Institutes of Health. As one of the originators of the oxidative hypothesis of atherosclerosis, he is credited with the co-discovery of oxidized low-density lipoprotein (ox-LDL) and has published extensively on oxidative stress in chronic diseases including atherosclerosis and endometriosis. He has been extensively involved in drug discovery and been a consultant for numerous major pharmaceutical companies including Bristol Myers Squibb, Johnson & Johnson and Vyrex Pharmaceuticals. Dr. Parthasarathy synthesized and patented water-soluble probucol at the University of California in San Diego and it was this compound that later formed the basis for AGI-1067 which was the lead product for Atherogenics, a pharmaceutical company based in Alpharetta, Georgia that raised nearly $700 million to advance this product. Dr. Parthasarathy holds several patent rights and has designed many of the key agents that are under investigation at InVasc Therapeutics.
Bertram Pitt, M.D.
Professor of Medicine, University of Michigan
Dr. Pitt is an acknowledged leader in the field of Cardiology and in pivotal international clinical trials. He was the principal investigator in the landmark RALES study on heart failure and PLAC study on atherosclerosis. Dr. Pitt has published over 300 papers in his professional career. He is also well-acknowledged by his consulting experiences with multiple pharmaceutical companies including: Pfizer, Takeda, Merck, Dai-Ichi Sankyo, Bayer, Boehringer-Ingelheim, Schering Plough and Astra Zeneca.
Dr. Sanjay Rajagopalan.M.D., Ph.D.
John W. Wolfe Professor of Medicine, Ohio State University
Dr. Rajagopalan is the Director of Vascular Medicine and Co-Director of Cardiovascular CT and MR Imaging at The Ohio State University School of Medicine and is one of InVasc Therapeutics' founder. He is a recognized expert in atherosclerotic vascular disease and has been involved for more than a decade in novel treatment strategies for atherosclerosis and at the forefront of bringing novel therapies to the clinic. Dr. Rajagopalan has been the national principal investigator for Phase I and II clinical trials involving emerging pharmacotherapies for atherosclerosis and is widely sought for his expertise in clinical trial design for lower extremity vascular disease. His expertise in vascular biology and imaging of atherosclerosis provides a unique strength for the imaging based design of pre-clinical and clinical studies targeting this disorder. Dr. Rajagopalan's laboratory currently focuses on understanding risk factors for atherosclerosis and the use of novel therapies to regress plaque. He has published more than 100 manuscripts, and over 125 scientific abstracts. He is currently a member of the Clinical Cardiovascular Science (CCVS) study section of the National Institutes of Health and is on the editorial board for Journal of the American College of Cardiology's Imaging Journal besides being a regular reviewer for multiple leading scientific journals.
